Company Profile // May 2012
1
Disclaimer
• This presentation has been prepared for the group of companies held by Clal
Biotechnology Industries Ltd. (“CBI” or “the Group”) and is provided to you solely for your
information and is not to be copied or distributed to any other person. This presentation
does not purport to be all-inclusive or to contain all of the information that may be relevant
in making any decision concerning an investment in the securities of the Group.
• No representation or warranty, express or implied, is made by any person as to the
accuracy or completeness of the information contained herein. In particular, no
representation or warranty is given as to the achievement of reasonableness of any
forecasts about the future prospects of the Group.
• This presentation does not constitute an offer or invitation to purchase or subscribe for any
securities, and neither this presentation nor anything contained herein shall form the basis
of or be relied upon in connection with any contract or commitment whatsoever.
2
About Us
• Established as an active investment company in
1998
• Publicly traded on Tel Aviv Stock Exchange
(TASE: CBI). Market Cap - $550M
§
Shareholders: Clal Industries &
Investments (57%), Teva (14%)
§
Focus: Advanced clinical stages of
innovative drug development
§
Investments: $800M invested in portfolio
companies ($200M by CBI) to date
§
Current portfolio: 12 diversified
investments
§
Pipeline: Blockbuster sales potential
CBI Shareholders
Public 28%
Teva 14%
CII 57%
• State of the art R&D facility and production plant
3
Diversified Portfolio: Stages
%
Company
Preclinical
Phase I
Phase II
Phase III
Market
38%
Polyheal
Sales
52%
MediWound
Registration
84%
Andromeda
Confirmatory
22%
Gamida Cell
Confirmatory /SPA
12%
CureTech
47%
D-Pharm
32%
BioCancell
23%
Avraham
25%
Biokine
15%
ProtAb
31%
VacciGuard
33%
Iluten
4
Diversified Portfolio: Therapeutic Clusters
Wound Care
CNS
CNS
Oncology
Immunology
Medical Devices
5
Management Team
Management
Industry Network
Avi Fischer, Chairman
Technology specialists
Ruben Krupik, CEO
Top scientists
Prof. Gabi Barabash (Sourasky Medical Center)
KOLs/ Physicians
Dr. Aharon Schwartz (Teva)
Pharma and Biotech executives
Ofer Gonen, Vice President
Patent & corporate lawyers
Ofer Goldberg, Vice President
Amos Bankirer, Vice President
Gil Milner, CFO
2006
2007
2008
2009
2010
GamidaCell
Andromeda
Mediwound
Andromeda
Aposense
Mediwound
Colbar
BioControl
TransPharma
D-Pharm
Polyheal
CureTech
TransPharma
CBI
Biomedical
MTRE
Remon
BioControl
IPO
Pharma
2011
M&A
6
Financials
300%
• TA 100 index, Biomed index,
Blue-tech 50 index
250%
200%
• Long term out performance vs.
benchmark
• Market Cap - $550M
150%
100%
• No debt
50%
0%
2008
2009
Clal Biotechnology
2010
NASDAQ Bio
2011
TA-100
2012
TASE Biomed
(M’ $)
2009
2010
2011
Profit
17
93
24
Liquid Assets
49
49
51
Shareholders Equity
135
263
286
R&D
27
36
38
Market Cap
367
506
512
7
Autoimmune Diseases
Andromeda
(84%)
• DiaPep277® : Novel immunotherapeutic agent for Type 1 Diabetes
• Blockbuster potential
• Technology: Hsp60 derived peptide immune modulates the immune system
• Strategic deal with Teva: Covers R&D + milestones (>$100M) + 20% royalties
• Phase III Europe (457 patients) - primary and clinical endpoints achieved
• significant preservation of C-peptide levels (23% between the groups,
p=0.037)
• Improved diabetic control measured by HbA1c levels (45.5% vs. 35.7%,
p=0.035)
• Phase Confirmatory Phase III (global) – On-going (450 patients, 120 centers)
8
Wound Care
Mediwound
(52%)
• NexoBrid™: Treatment of severe burns, potential market $500M
• Technology: Enzymatic eschar removal
• Phase III – completed successfully (175 patients)
• rapid eschar removal (0.8 days vs. 6.7 days, p<0.0001)
• reduction in wound area surgically excised (13.1% vs. 56.7%, p<0.0001)
• Registration process in EU. Phase III in the US to begin shortly
Polyheal
(38%)
• PolyHeal™: Treating hard to heal wounds, potential market $500M
• Technology: Charged microspheres
• Successful and significant clinical results (>250 patients)
• creation of granulation tissue (46.9% vs. 15.4%, p<0.02)
• reduction of wound size (-39% vs. -14.8%, p<0.03)
• EU launch in 2012
Strategic partnership between Teva, Mediwound and Polyheal:
Teva covers all R&D + milestones (>$300M) + royalties
9
Oncology
CureTech
(12%)
• CT-011 : An antibody for several types of cancer diseases
• Technology: Immune-modulating antibody
• Collaboration agreement with Teva: R&D + milestones ($250M) + 6% royalties
• 6 Phase II studies – on-going (>400 patients)
• Lymphoma (DLBCL) results: reduced rate of progression (PFS 69% vs. 58%)
and improved survival (OS 85% vs. 69%)
Gamida Cell
(22%)
• StemEx ®: Cell therapy in the area of bone marrow transplantation
• Technology: Expansion of stem cells derived from umbilical cord blood
• Pivotal Phase III study under SPA , 100 patients, Open label, Fast track
10
Value Creating Milestones
Andromeda
Phase III
Results
Medical
Device Fund
Launch
Avraham
Phase II - MCI
Initiation
Q42011
Q12012
Avraham
Phase II - AD
Interim results
CureTech
Strategic Deal
with Teva
MediWound
EU Marketing
Approval
Gamida Cell
Phase III
Results
Biokine
Phase II
Initiation
Q22012
BioCancell
Phase II
Initiation
D-Pharm
Phase III
Interim Results
Thrombotech
Phase II
Results
Q32012
Q42012
BioCancell
Phase II
Results
PiR Squared
First in Man
Q22013
Q12013
CureTech
Phase II
Results
MediWound
Phase III
Initiation
ProtAb
Phase I
Initiation
CureTech
Phase III
Initiation
Significant Milestone
Milestone
11
Clal Biotechnology Industries Summary
12
5
20
50
65
Portfolio
Companies
Phase III
Compounds
Pipeline
Products
$M
Liquidity
$M Medical
Device Fund
12